Want to see AU:FRE full AI Analyst Report?
Top Page
Firebrick Pharma Limited
(Sydney:FRE)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.03
â–¼(-38.00% Downside)
Action:Reiterated
Date:06/21/26
The score is held down primarily by weak financial performance (sharp revenue decline, large ongoing losses, and persistent cash burn), reinforced by bearish technicals with the price below major moving averages and negative MACD. A debt-free balance sheet provides some stability, but valuation signals are limited due to negative earnings and no dividend support.
Positive Factors
Low leverage / debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving management flexibility to fund R&D or absorb variability in revenues without immediate refinancing. This durability supports survival through development cycles and extends runway versus leveraged peers.
Negative Factors
Sharp revenue decline
A ~74% revenue drop is a structural red flag for commercialization, demand, or contract continuity. Such a large fall impairs fixed-cost absorption, undermines scale economics, and makes it harder to convert positive gross margin into operating profit without a clear, durable recovery in sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving management flexibility to fund R&D or absorb variability in revenues without immediate refinancing. This durability supports survival through development cycles and extends runway versus leveraged peers.
Read all positive factors
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$10.55M
Dividend YieldN/A
Average Volume (3M)91.61K
Price to Earnings (P/E)―
Beta (1Y)-0.26
Revenue Growth-24.30%
EPS Growth-23.26%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.01
Shares Outstanding285,198,970
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firebrick Pharma Limited Business Overview & Revenue Model
Company Description
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Austr...
How the Company Makes Money
null...
Firebrick Pharma Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 381.71K | 293.42K | 14.52K | 830.00 | 4.12K | 422.00K |
| Gross Profit | -260.68K | 104.82K | -22.78K | 830.00 | 4.12K | 421.48K |
| EBITDA | -2.45M | -2.86M | -1.17M | -6.81M | -4.86M | -2.86M |
| Net Income | -2.45M | -2.63M | -1.18M | -6.80M | -3.80M | -2.44M |
Balance Sheet | ||||||
| Total Assets | 2.28M | 1.83M | 2.41M | 2.98M | 8.73M | 11.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 983.35K | 824.78K | 2.35M | 7.14M | 11.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 341.73K | 271.28K | 291.07K | 506.44K | 450.10K | 214.80K |
| Stockholders Equity | 1.94M | 1.56M | 2.12M | 2.48M | 8.28M | 11.55M |
Cash Flow | ||||||
| Free Cash Flow | -2.25M | -1.86M | -2.35M | -5.78M | -4.23M | -1.95M |
| Operating Cash Flow | -2.24M | -1.78M | -2.34M | -5.78M | -4.20M | -1.94M |
| Investing Cash Flow | -16.50K | -82.98K | -134.00 | -1.62K | -32.54K | -16.07K |
| Financing Cash Flow | 2.78M | 2.02M | 815.21K | 996.65K | 10.23M | 3.01M |
Firebrick Pharma Limited Technical Analysis
Negative
0.05
Price Trends
0.04
Negative
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
52.42
Neutral
60.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:FRE, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 60.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:FRE.
Firebrick Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$224.24M | -2.60 | -23.02% | ― | -1.55% | 35.60% | |
45 Neutral | AU$57.42M | -0.45 | -131.13% | ― | 2086.71% | -116.20% | |
44 Neutral | AU$12.85M | -0.26 | 1068.18% | ― | ― | 40.85% | |
43 Neutral | AU$10.55M | -3.49 | -140.26% | ― | -24.30% | -23.26% | |
43 Neutral | AU$11.62M | -1.87 | -43.95% | ― | 14.30% | 41.93% | |
42 Neutral | AU$12.75M | -2.17 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:FRE
Firebrick Pharma Limited
0.04
-0.02
-39.34%
AU:MYX
Mayne Pharma Group
2.76
-2.31
-45.56%
AU:IMC
Immuron Limited
0.04
-0.03
-42.86%
AU:1AD
AdAlta Ltd.
―
―
―
AU:IDT
IDT Australia Limited
0.03
-0.07
-69.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.29
-93.23%
Firebrick Pharma Limited Corporate Events
Firebrick Pharma shareholders back all resolutions at General Meeting
Jun 22, 2026
Firebrick Pharma reported that all resolutions put to shareholders at its General Meeting on 22 June 2026 were passed by poll, including ratifications of prior share and option issues under various ASX listing rules. The strong support for these m...
Firebrick Pharma extends Nasodine patent protection with New Zealand grant
Jun 2, 2026
Firebrick Pharma has secured a New Zealand patent for the pharmaceutical composition of its Nasodine Nasal Spray, adding to existing grants in Australia and South Africa and filings in major markets including the United States and Europe. The pate...
Firebrick Pharma issues shares to consultant in lieu of fees
Jun 1, 2026
Firebrick Pharma Limited has issued 220,000 ordinary fully paid shares to a consultant in lieu of service fees, at an issue price of $0.05 per share. The company stated that these shares were issued without the need for a prospectus under the Corp...
Firebrick Pharma Seeks ASX Quotation for Additional Shares
Jun 1, 2026
Firebrick Pharma has applied to the ASX for quotation of 220,000 additional ordinary fully paid shares under the code FRE. The new securities, issued on 2 June 2026, modestly expand the company’s listed capital base and may provide increment...
Firebrick Pharma Plans Placement of 220,000 New Shares
May 31, 2026
Firebrick Pharma Limited has notified the ASX of a proposed issue of 220,000 new fully paid ordinary shares under a placement or similar equity issuance. The new securities, scheduled for issue on June 2, 2026, represent an additional capital-rais...
Firebrick Pharma Options Lapse, Simplifying Capital Structure
May 31, 2026
Firebrick Pharma Limited has confirmed that 8,000,000 options, exercisable at $0.075 and expiring on 28 May 2026, have lapsed unexercised, resulting in a reduction in its outstanding options on issue. This cessation of securities simplifies the co...
Firebrick Pharma Calls Virtual Meeting to Ratify Key Share and Option Issues
May 22, 2026
Firebrick Pharma Limited has called a virtual general meeting of shareholders for 22 June 2026, enabling investors to attend online via a platform powered by Automic, submit questions and vote, with eligibility determined as of 20 June 2026. The m...
Firebrick Pharma Director Increases Indirect Shareholding via On-Market Purchase
May 21, 2026
Firebrick Pharma Limited has disclosed a change in the indirect shareholding of director Peter Laurence Molloy, as required under ASX listing rules. The notice states that Molloy’s relevant interest is held through his associate, Christine L...
Firebrick Pharma wins Canadian patent for Nasodine COVID-19 use
May 13, 2026
Firebrick Pharma has secured Canadian acceptance of a key patent covering its Nasodine Nasal Spray and other intranasal povidone-iodine products for reducing SARS-CoV-2 viral load in the nose and for pre-exposure prophylaxis against COVID-19. This...
Firebrick Pharma to Brief Investors After Nasodine Approval and $1.5m Placement
Apr 22, 2026
Firebrick Pharma will host an investor webinar on 27 April 2026 to brief shareholders and potential investors on recent developments, including the approval of its Nasodine Nasal Spray in Indonesia and completion of a $1.5 million placement. The s...
Firebrick Pharma ramps up Nasodine rollout and global push with new capital and hires
Apr 21, 2026
Firebrick Pharma reported significant progress in the March 2026 quarter, highlighted by regulatory approval of its Nasodine Nasal Spray in Indonesia, Southeast Asia’s largest market, and the launch of Nasodine Throat Spray in Singapore and ...
Firebrick Pharma Issues 6.38 Million Unquoted Options Expiring 2028
Apr 20, 2026
Firebrick Pharma has notified the market of the issue of 6,382,980 unquoted options, exercisable at $0.095 and expiring on 4 July 2028. The options, recorded under ASX code FREAF, were issued on 20 April 2026 as part of previously announced transa...
Firebrick Pharma Investor Goodall Sees Voting Power Diluted After Private Placement
Apr 17, 2026
Firebrick Pharma shareholder Stephen Francis Goodall and related entities have disclosed an unchanged holding of 31,038,290 fully paid ordinary shares, but their voting power has fallen from 12.43% to 10.90% following a dilutionary private placeme...
Firebrick Pharma Private Placement Dilutes Major Shareholder’s Voting Power
Apr 17, 2026
Firebrick Pharma has disclosed a change in the voting power of substantial shareholder Peter Laurence Molloy and his related parties, following a private placement completed on 31 March 2026. While Molloy and associated entities continue to hold 3...
Firebrick Pharma Issues 1 Million Unlisted Employee Options
Apr 16, 2026
Firebrick Pharma Limited has issued 1,000,000 unlisted options as part of its employee incentive arrangements, with the options expiring on 17 April 2030 and carrying an exercise price of $0.15. The move underscores the company’s use of equi...
Firebrick Pharma Seeks ASX Quotation for Over 10.6 Million New Shares
Apr 16, 2026
Firebrick Pharma Limited has applied for quotation on the ASX of 10,638,297 ordinary fully paid shares under code FRE, with an issue date of 17 April 2026. The move increases the number of tradeable securities on market, potentially enhancing liqu...
Firebrick Pharma Announces Expiry of 180,000 Unexercised Options
Apr 13, 2026
Firebrick Pharma Limited has notified the ASX of the cessation of 180,000 options, which expired unexercised on April 1, 2026. The expiry of these options marginally reduces the company’s potential diluted share count and reflects routine ma...
Firebrick Pharma Issues Over 21.6 Million New Shares and Confirms Regulatory Compliance
Apr 13, 2026
Firebrick Pharma has issued 21,636,603 new ordinary fully paid shares, comprising 21,276,603 shares from a recent placement at $0.047 each and 360,000 shares from the exercise of options at $0.0217. The company confirmed the shares were issued wit...
Firebrick Pharma Issues 10.6 Million Unquoted Options Expiring in 2028
Apr 13, 2026
Firebrick Pharma Limited has issued 10,638,304 unquoted options with an exercise price of $0.095, expiring on July 4, 2028, as notified in its latest Appendix 3G filing. These options, which are not intended to be quoted on the ASX, form part of p...
Firebrick Pharma Applies to Quote 21.3 Million New Shares on ASX
Apr 13, 2026
Firebrick Pharma Limited has lodged an application with the ASX for quotation of 21,276,603 new ordinary fully paid shares, to be issued and quoted from April 13, 2026. The enlarged pool of quoted securities, arising from previously flagged transa...
Firebrick Pharma Seeks Quotation of 360,000 New Ordinary Shares on ASX
Apr 13, 2026
Firebrick Pharma Limited has applied for quotation of 360,000 new fully paid ordinary shares on the ASX, with an issue date of April 13, 2026. The new securities arise from the exercise or conversion of existing options or other convertible instru...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.